ID

20307

Description

Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study; ODM derived from: https://clinicaltrials.gov/show/NCT00343395

Link

https://clinicaltrials.gov/show/NCT00343395

Keywords

  1. 2/20/17 2/20/17 -
Uploaded on

February 20, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Coronary Artery Disease NCT00343395

Eligibility Coronary Artery Disease NCT00343395

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
the patient (male or non-pregnant female) must be > 18 years of age.
Description

Age | Pregnancy

Data type

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0032961
the patient or legally authorized representative must sign a written informed consent, prior to the procedure, using a form that is approved by the local institutional review board.
Description

Informed Consent | Informed Consent Patient Representatives

Data type

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2,1]
C0021430
UMLS CUI [2,2]
C0030701
angiographically documented coronary artery disease defined as the presence of at least one 50% or greater stenosis of a major coronary artery.
Description

Coronary Artery Disease angiography | Coronary artery Major Percent Diameter Stenosis Measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C1956346
UMLS CUI [1,2]
C0002978
UMLS CUI [2,1]
C0205042
UMLS CUI [2,2]
C0205164
UMLS CUI [2,3]
C3897965
stabilized post any prior acs event (i.e., without ongoing ischemic rest pain, congestive heart failure, or malignant arrhythmias) for at least 3 months
Description

Stabilization Post Acute Coronary Syndrome | Ischemic pain At rest | Congestive heart failure | Cardiac Arrhythmia Malignant

Data type

boolean

Alias
UMLS CUI [1,1]
C1293130
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C0948089
UMLS CUI [2,1]
C0745417
UMLS CUI [2,2]
C0443144
UMLS CUI [3]
C0018802
UMLS CUI [4,1]
C0003811
UMLS CUI [4,2]
C0205282
fasting blood glucose 87-125 mg/dl
Description

Fasting blood glucose measurement

Data type

boolean

Alias
UMLS CUI [1]
C0428568
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
age <18 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
known hypersensitivity to metformin or rosiglitazone
Description

Metformin allergy | Hypersensitivity rosiglitazone

Data type

boolean

Alias
UMLS CUI [1]
C0571648
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0289313
renal insufficiency defined as calculated creatinine clearance (crcl) <40 ml/min using the following formula:
Description

Renal Insufficiency | Estimation of creatinine clearance by Cockcroft-Gault formula

Data type

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C2711451
men: crcl (ml/min) = weight (kg) x (140-age) 72 x serum creatinine (mg/dl) women: 0.85 x the value calculated for men
Description

Estimation of creatinine clearance by Cockcroft-Gault formula | Gender

Data type

boolean

Alias
UMLS CUI [1]
C2711451
UMLS CUI [2]
C0079399
pregnant and/or lactating women, and women of child bearing potential are excluded from this trial
Description

Pregnancy | Breast Feeding | Childbearing Potential

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C3831118
co-morbidity such that the patient is not expected to survive >2 years
Description

Comorbidity | Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0009488
UMLS CUI [2]
C0023671
current therapy with rosiglitazone or metformin
Description

rosiglitazone | Metformin

Data type

boolean

Alias
UMLS CUI [1]
C0289313
UMLS CUI [2]
C0025598
pci within the previous six months (other than for the qualifying event)
Description

Percutaneous Coronary Intervention

Data type

boolean

Alias
UMLS CUI [1]
C1532338
prior cabg within the previous two months, scheduled cabg, or a decision to perform cabg made prior to enrollment
Description

Coronary Artery Bypass Surgery | Coronary Artery Bypass Surgery Scheduled | Coronary Artery Bypass Surgery Perform Decision

Data type

boolean

Alias
UMLS CUI [1]
C0010055
UMLS CUI [2,1]
C0010055
UMLS CUI [2,2]
C0205539
UMLS CUI [3,1]
C0010055
UMLS CUI [3,2]
C0884358
UMLS CUI [3,3]
C0679006
overt diabetes mellitus (fbg>126 or antidiabetic therapy)
Description

Diabetes Mellitus | Fasting blood glucose measurement | Antidiabetics

Data type

boolean

Alias
UMLS CUI [1]
C0011849
UMLS CUI [2]
C0428568
UMLS CUI [3]
C0935929
any diagnosis of congestive heart failure
Description

Congestive heart failure

Data type

boolean

Alias
UMLS CUI [1]
C0018802
obstructive hepatobiliary disease or other significant hepatic disease (defined as the presence of at least one of the following: ast, alt, ggt, total bilirubin, or alkaline phosphatase >3x upper limit normal, not related to mi
Description

Hepatobiliary disease Obstructive | Liver disease | Aspartate aminotransferase increased | Alanine aminotransferase increased | Gamma-glutamyl transferase raised | Elevated total bilirubin | Alkaline phosphatase raised | Myocardial Infarction Relationship Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C0267792
UMLS CUI [1,2]
C0549186
UMLS CUI [2]
C0023895
UMLS CUI [3]
C0151904
UMLS CUI [4]
C0151905
UMLS CUI [5]
C0151662
UMLS CUI [6]
C0741494
UMLS CUI [7]
C0151849
UMLS CUI [8,1]
C0027051
UMLS CUI [8,2]
C0439849
UMLS CUI [8,3]
C0332197
participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study.
Description

Study Subject Participation Status | Investigational New Drugs | product marketing

Data type

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
UMLS CUI [3]
C0683746

Similar models

Eligibility Coronary Artery Disease NCT00343395

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age | Pregnancy
Item
the patient (male or non-pregnant female) must be > 18 years of age.
boolean
C0001779 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
Informed Consent | Informed Consent Patient Representatives
Item
the patient or legally authorized representative must sign a written informed consent, prior to the procedure, using a form that is approved by the local institutional review board.
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C0030701 (UMLS CUI [2,2])
Coronary Artery Disease angiography | Coronary artery Major Percent Diameter Stenosis Measurement
Item
angiographically documented coronary artery disease defined as the presence of at least one 50% or greater stenosis of a major coronary artery.
boolean
C1956346 (UMLS CUI [1,1])
C0002978 (UMLS CUI [1,2])
C0205042 (UMLS CUI [2,1])
C0205164 (UMLS CUI [2,2])
C3897965 (UMLS CUI [2,3])
Stabilization Post Acute Coronary Syndrome | Ischemic pain At rest | Congestive heart failure | Cardiac Arrhythmia Malignant
Item
stabilized post any prior acs event (i.e., without ongoing ischemic rest pain, congestive heart failure, or malignant arrhythmias) for at least 3 months
boolean
C1293130 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C0948089 (UMLS CUI [1,3])
C0745417 (UMLS CUI [2,1])
C0443144 (UMLS CUI [2,2])
C0018802 (UMLS CUI [3])
C0003811 (UMLS CUI [4,1])
C0205282 (UMLS CUI [4,2])
Fasting blood glucose measurement
Item
fasting blood glucose 87-125 mg/dl
boolean
C0428568 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Age
Item
age <18 years
boolean
C0001779 (UMLS CUI [1])
Metformin allergy | Hypersensitivity rosiglitazone
Item
known hypersensitivity to metformin or rosiglitazone
boolean
C0571648 (UMLS CUI [1])
C0020517 (UMLS CUI [2,1])
C0289313 (UMLS CUI [2,2])
Renal Insufficiency | Estimation of creatinine clearance by Cockcroft-Gault formula
Item
renal insufficiency defined as calculated creatinine clearance (crcl) <40 ml/min using the following formula:
boolean
C1565489 (UMLS CUI [1])
C2711451 (UMLS CUI [2])
Estimation of creatinine clearance by Cockcroft-Gault formula | Gender
Item
men: crcl (ml/min) = weight (kg) x (140-age) 72 x serum creatinine (mg/dl) women: 0.85 x the value calculated for men
boolean
C2711451 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
Pregnancy | Breast Feeding | Childbearing Potential
Item
pregnant and/or lactating women, and women of child bearing potential are excluded from this trial
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3])
Comorbidity | Life Expectancy
Item
co-morbidity such that the patient is not expected to survive >2 years
boolean
C0009488 (UMLS CUI [1])
C0023671 (UMLS CUI [2])
rosiglitazone | Metformin
Item
current therapy with rosiglitazone or metformin
boolean
C0289313 (UMLS CUI [1])
C0025598 (UMLS CUI [2])
Percutaneous Coronary Intervention
Item
pci within the previous six months (other than for the qualifying event)
boolean
C1532338 (UMLS CUI [1])
Coronary Artery Bypass Surgery | Coronary Artery Bypass Surgery Scheduled | Coronary Artery Bypass Surgery Perform Decision
Item
prior cabg within the previous two months, scheduled cabg, or a decision to perform cabg made prior to enrollment
boolean
C0010055 (UMLS CUI [1])
C0010055 (UMLS CUI [2,1])
C0205539 (UMLS CUI [2,2])
C0010055 (UMLS CUI [3,1])
C0884358 (UMLS CUI [3,2])
C0679006 (UMLS CUI [3,3])
Diabetes Mellitus | Fasting blood glucose measurement | Antidiabetics
Item
overt diabetes mellitus (fbg>126 or antidiabetic therapy)
boolean
C0011849 (UMLS CUI [1])
C0428568 (UMLS CUI [2])
C0935929 (UMLS CUI [3])
Congestive heart failure
Item
any diagnosis of congestive heart failure
boolean
C0018802 (UMLS CUI [1])
Hepatobiliary disease Obstructive | Liver disease | Aspartate aminotransferase increased | Alanine aminotransferase increased | Gamma-glutamyl transferase raised | Elevated total bilirubin | Alkaline phosphatase raised | Myocardial Infarction Relationship Absent
Item
obstructive hepatobiliary disease or other significant hepatic disease (defined as the presence of at least one of the following: ast, alt, ggt, total bilirubin, or alkaline phosphatase >3x upper limit normal, not related to mi
boolean
C0267792 (UMLS CUI [1,1])
C0549186 (UMLS CUI [1,2])
C0023895 (UMLS CUI [2])
C0151904 (UMLS CUI [3])
C0151905 (UMLS CUI [4])
C0151662 (UMLS CUI [5])
C0741494 (UMLS CUI [6])
C0151849 (UMLS CUI [7])
C0027051 (UMLS CUI [8,1])
C0439849 (UMLS CUI [8,2])
C0332197 (UMLS CUI [8,3])
Study Subject Participation Status | Investigational New Drugs | product marketing
Item
participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0683746 (UMLS CUI [3])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial